HAIMBIO
HaimBio is a drug development company. Their flagship product, Starvanip, is a metabolism-based cancer therapy that kills cancer cells by starving them of metabolic energy. Starvanip inhibits cancer cell growth and induces apoptosis -- the death of cancer cells. It does this by inhibiting the energy source of cancer cells, dramatically reducing side effects such as harm to normal cells and reducing the toxicity of current anticancer therapies. The drug will also improve the rate of response and target a wider range of cancers. Tests have demonstrated efficacy with 12 types of cancer, as well as significant reductions of tumor sizes and increases of cancer cell death with almost no death of normal cells.
HAIMBIO
Social Links:
Industry:
Biotechnology Medical
Founded:
2011-09-26
Address:
Seoul, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Website Url:
http://www.en.haimbio.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
3 M KRW
Technology used in webpage:
SPF ASP.NET IIS IIS 10 Japanese Yen GlobalSign Classic ASP Naver Analytics
Similar Organizations
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.en.haimbio.com
- Host name: 211.47.74.128
- IP address: 211.47.74.128
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "HaimBio"
About Us_AIM Bio
We acquired 50.1546% equities of Liverna to further accelerate research of mRNA COVID-19 vaccine and production layout.See details»
Home_AIM Bio
Rabies vaccine combination under development for human use. Such combination covers the globally innovative mRNA rabies vaccine under development, human diploid cell based rabies vaccine for human use as …See details»
AIM Vaccine Co., Ltd – DCVMN
AIM Vaccine Co., Ltd. (referred to as “AIM”), committing to develop and manufacture top quality vaccines to safeguard the health of the world, is a major vaccine company in China, which covers the full value chain from research …See details»
AIM Vaccine - Crunchbase Company Profile & Funding
Contact Email [email protected] AIM Vaccine is a full-chain vaccine corporation that boasts a comprehensive presence from R&D to commercialization. Armed with 5 …See details»
R&D_AIM Bio
Rabies vaccine combination under development for human use. Such combination covers the globally innovative mRNA rabies vaccine under development, human diploid cell based rabies vaccine for human use as …See details»
关于艾美_艾美疫苗 - aimbio.com
2017年9月至2019年1月，收购艾美坚持（原艾美卫信）的全部股权，自此艾美坚持成为艾美疫苗全资子公司。艾美坚持于2007年9月取得肾综合征出血热疫苗的新药申请 批准，2008年2月取 …See details»
Company-Hangzhou Zhunxin Biotechnology Co.,Ltd.
Aimbio Make diagnostic better, easier, faster Company Culture Company We established in Hangzhou,China in 2018. We are dedicated to make molecular diagnostic faster, easier and better. We are committed to the R&D and …See details»
AIM Vaccine - Products, Competitors, Financials, Employees ...
Oct 6, 2022 en.aimbio.com. Overview & Products; Financials; Founded Year 2012. Stage IPO | IPO. Date of IPO 10/6/2022. Market Cap 9.88B. Stock Price 7.40. Revenue ... In accordance …See details»
首页_艾美疫苗
艾美疫苗是一家专业生产重组乙型肝炎疫苗的企业，致力于基因工程疫苗技术的开发研究。See details»
The Aimei Hepatitis B vaccine ignited the Spark Project, …
They also aim to use high-quality hepatitis B vaccines to contribute to controlling the spread of the hepatitis B virus, achieving the World Health Organization's goal of eliminating viral hepatitis …See details»
Home - AIM Biotech
AIM Biotech is leading the shift from preclinical animal models to humanized in vitro physiological models for the discovery of new medicines.. Researchers and regulators around the globe …See details»
财务报告_投资者关系_艾美疫苗 - aimbio.com
数据截止： （北京时间) 报价有十五分钟或以上延迟 资料/数据来源： 新浪财经See details»
Hangzhou Zhunxin Biotechnology Co.,Ltd._Nucleic acid test …
AIMBIO ( 2 hours ) 01 Taking Sample 02 AIMDX 1800 03 Report Logistics After-sales telephone European Office WhatsApp. 5 +852 56076375 Email. 8. [email protected] Tel. 9 …See details»
Rising Star of International First-line Vaccine AIM Vaccine MCV4 ...
Another success of AIM Vaccine Co., Ltd.—its wholly-owned subsidiary AIM Vacin obtained the Notice of Approval for Drug Clinical Trial for its ACYW135 Meningococcus Conjugate Vaccine …See details»
公告 | 艾美疫苗mRNA RSV与mRNA带状疱疹疫苗向FDA提交临床试 …
本集团按照既定公司战略积极推进疫苗产品管线的开发，利用mrna技术平台优 势，通过持续的技术创新，快速推进mrna疫苗系列产品的研发，并已于2024年8月首次向美国食品和药品监督管 …See details»
Aimbio - LinkedIn
Aimbio is a leading manufacturer of high-quality, automated PCR systems and reagents. Our innovative products are designed to streamline the PCR process in veterinary clinics and …See details»
Dynamics_News_AIM Bio
The board of directors of the Company (the “Board”) is pleased to announce that on March 2, 2024, the randomized, blinded and comparable vaccine-controlled Phase II clinical trial of the …See details»
Human Genome Organisation - Wikipedia
The Human Genome Organisation (HUGO) is a non-profit organization founded in 1988.HUGO represents an international coordinating scientific body in response to initiatives such as the …See details»
公告 | 迭代无血清狂犬病疫苗临床III期数据揭盲达到临床预设目 …
本公司董事会（「董事会」）欣然宣布，本集团近日获得中国食品药品检定研究院关于无血清迭代狂犬病疫苗iii期临床试验血清抗体检测结果的通知，截止目前，本集团无血清迭代狂犬病疫 …See details»
Media Reports_News_AIM Bio
This year's Nobel Prize once again dominated the hot topics list with the previously renowned mRNA technology. The good news is that the leading vaccine company Aimei Vaccine …See details»